Development of ZYL-314
In the development of ZYL-314 we used a novel approach. First, we identified a well-known compound which is known to increase BDNF levels indirectly, and which may also bind directly to TrkB receptors. However, this active compound is highly reactive to oxygen and therefore unstable. We therefore built a way to safely encapsulate this compound in the form of a stable co-crystal salt, which allows the active compound to be rapidly absorbed after oral administration.
Our novel approach allows a known, safe and effective compound to be rapidly available to further enhance its efficacy. Importantly, the preclinical research we have completed shows that ZYL-314 has multiple neuroplasticity effects and appears to be a highly robust enhancer of BDNF/TrkB activation, even after very small oral doses. This opens the possibility of wide spread use if these preclinical results are replicated in patients.